Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS With Diabetic Peripheral Neuropathic Pain (PROGRESS)

NCT06203002 is registered in ClinicalTrials.gov with Lexicon Pharmaceuticals as lead sponsor.

NCT NCT06203002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06203002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS With Diabetic Peripheral Neuropathic Pain (PROGRESS)
Lead sponsor
Lexicon Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2023
Completion date
February 24, 2025
Enrollment
496 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathic pain